Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Fiche publication
Date publication
septembre 2022
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Olivera PA, Lasa JS, Zubiaurre I, Jairath V, Abreu MT, Rubin DT, Reinisch W, Magro F, Rahier JF, Danese S, Rabaud C, Peyrin-Biroulet L
Lien Pubmed
Résumé
Advanced therapies for inflammatory bowel disease (IBD) could potentially lead to a state of immunosuppression with an increased risk of opportunistic infections (OIs). We aimed to update on the incidence of OIs among adult IBD patients in randomized controlled trials (RCTs) of approved biologics and small-molecule drugs (SMDs). Also, we aim to describe OIs definitions utilized in RCTs, to ultimately propose a standardized definition.
Mots clés
‘biologic’, ‘opportunistic infections’, ‘small-molecule drugs’
Référence
J Crohns Colitis. 2022 09 10;: